These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 31986520)

  • 21. Effect of Suvorexant vs Placebo on Total Daytime Sleep Hours in Shift Workers: A Randomized Clinical Trial.
    Zeitzer JM; Joyce DS; McBean A; Quevedo YL; Hernandez B; Holty JE
    JAMA Netw Open; 2020 Jun; 3(6):e206614. PubMed ID: 32484552
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: analysis of pooled phase 3 data.
    Snyder E; Ma J; Svetnik V; Connor KM; Lines C; Michelson D; Herring WJ
    Sleep Med; 2016 Mar; 19():93-100. PubMed ID: 27198953
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Suvorexant: scientifically interesting, utility uncertain.
    Keks NA; Hope J; Keogh S
    Australas Psychiatry; 2017 Dec; 25(6):622-624. PubMed ID: 28994603
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Addition of Suvorexant to Ramelteon Therapy for Improved Sleep Quality with Reduced Delirium Risk in Acute Stroke Patients.
    Kawada K; Ohta T; Tanaka K; Miyamura M; Tanaka S
    J Stroke Cerebrovasc Dis; 2019 Jan; 28(1):142-148. PubMed ID: 30322756
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety profile and clinical course of patients with insomnia administered suvorexant by initial treatment status in a post-marketing survey.
    Sano H; Asai Y; Miyazaki M; Iwakura M; Maeda Y; Hara M
    Expert Opin Drug Saf; 2019 Nov; 18(11):1109-1118. PubMed ID: 31478753
    [No Abstract]   [Full Text] [Related]  

  • 26. Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials.
    Herring WJ; Connor KM; Ivgy-May N; Snyder E; Liu K; Snavely DB; Krystal AD; Walsh JK; Benca RM; Rosenberg R; Sangal RB; Budd K; Hutzelmann J; Leibensperger H; Froman S; Lines C; Roth T; Michelson D
    Biol Psychiatry; 2016 Jan; 79(2):136-48. PubMed ID: 25526970
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of suvorexant in the prevention of delirium during acute hospitalization: A systematic review.
    Adams AD; Pepin MJ; Brown JN
    J Crit Care; 2020 Oct; 59():1-5. PubMed ID: 32480359
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adverse reaction with suvorexant for insomnia: acute worsening of depression with emergence of suicidal thoughts.
    Petrous J; Furmaga K
    BMJ Case Rep; 2017 Oct; 2017():. PubMed ID: 29066641
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insight Into Reduction of Wakefulness by Suvorexant in Patients With Insomnia: Analysis of Wake Bouts.
    Svetnik V; Snyder ES; Tao P; Scammell TE; Roth T; Lines C; Herring WJ
    Sleep; 2018 Jan; 41(1):. PubMed ID: 29112763
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Suvorexant: a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia.
    Patel KV; Aspesi AV; Evoy KE
    Ann Pharmacother; 2015 Apr; 49(4):477-83. PubMed ID: 25667197
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Suvorexant for the treatment of insomnia in patients with Alzheimer's disease.
    Hamuro A; Honda M; Wakaura Y
    Aust N Z J Psychiatry; 2018 Feb; 52(2):207-208. PubMed ID: 29237271
    [No Abstract]   [Full Text] [Related]  

  • 32. Suvorexant is associated with a low incidence of delirium in critically ill patients: a retrospective cohort study.
    Masuyama T; Sanui M; Yoshida N; Iizuka Y; Ogi K; Yagihashi S; Nagatomo K; Sasabuchi Y; Lefor AK
    Psychogeriatrics; 2018 May; 18(3):209-215. PubMed ID: 29423967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-selective orexin-receptor antagonist attenuates stress-re-stress-induced core PTSD-like symptoms in rats: Behavioural and neurochemical analyses.
    Prajapati SK; Krishnamurthy S
    Behav Brain Res; 2021 Feb; 399():113015. PubMed ID: 33212086
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Suvorexant for the treatment of insomnia.
    Jacobson LH; Callander GE; Hoyer D
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):711-30. PubMed ID: 25318834
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preventive Effect of Suvorexant for Postoperative Delirium after Coronary Artery Bypass Grafting.
    Tamura K; Maruyama T; Sakurai S
    Ann Thorac Cardiovasc Surg; 2019 Feb; 25(1):26-31. PubMed ID: 30089761
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study.
    Schoedel KA; Sun H; Sellers EM; Faulknor J; Levy-Cooperman N; Li X; Kennedy WP; Cha JH; Lewis NM; Liu W; Bondiskey P; McCrea JB; Panebianco DL; Troyer MD; Wagner JA
    J Clin Psychopharmacol; 2016 Aug; 36(4):314-23. PubMed ID: 27253658
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prescription Drugs Used in Insomnia.
    Dujardin S; Pijpers A; Pevernagie D
    Sleep Med Clin; 2020 Jun; 15(2):133-145. PubMed ID: 32386689
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neurophysiological and Behavioral Effects of Anti-Orexinergic Treatments in a Mouse Model of Huntington's Disease.
    Cabanas M; Pistono C; Puygrenier L; Rakesh D; Jeantet Y; Garret M; Cho YH
    Neurotherapeutics; 2019 Jul; 16(3):784-796. PubMed ID: 30915710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of suvorexant on the Insomnia Severity Index in patients with insomnia: analysis of pooled phase 3 data.
    Herring WJ; Connor KM; Snyder E; Snavely DB; Morin CM; Lines C; Michelson D
    Sleep Med; 2019 Apr; 56():219-223. PubMed ID: 30522875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Orexin receptor antagonists: a new treatment for insomnia?
    Riemann D; Spiegelhalder K
    Lancet Neurol; 2014 May; 13(5):441-3. PubMed ID: 24680373
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.